Literature DB >> 10817953

The epidemiology of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).

.   

Abstract

Progressive supranuclear palsy (PSP, also known as Steele-Richardson-Olszewski syndrome) is relatively uncommon. Studies to date have found a crude population prevalence for PSP of between 1.39 and 4.9 cases per 100,000. An increased awareness of the condition, together with recently formulated clinical diagnostic criteria, should facilitate future descriptive epidemiological studies.Possible aetiological influences both genetic (tau polymorphisms) and environmental (herbal tea and tropical fruit consumption in the French West Indies) have recently been postulated. Future studies into both disease prevalence and aetiology would benefit from a multi-centre approach.

Entities:  

Year:  2000        PMID: 10817953     DOI: 10.1016/s1353-8020(00)00011-0

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  8 in total

1.  The potential research impact of patient reported outcomes on osteogenesis imperfecta.

Authors:  Catherine A Brownstein; Paul Wicks
Journal:  Clin Orthop Relat Res       Date:  2010-10       Impact factor: 4.176

2.  Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy.

Authors:  A Padovani; B Borroni; S M Brambati; C Agosti; M Broli; R Alonso; P Scifo; G Bellelli; A Alberici; R Gasparotti; D Perani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11-23       Impact factor: 10.154

Review 3.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Population based mortality and quality of death certification in progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).

Authors:  U Nath; R Thomson; R Wood; Y Ben-Shlomo; A Lees; C Rooney; D Burn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

5.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

6.  The economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United Kingdom.

Authors:  Paul McCrone; Christine Anne Mary Payan; Martin Knapp; Albert Ludolph; Yves Agid; P Nigel Leigh; Gilbert Bensimon
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

7.  Brain alterations and mini-mental state examination in patients with progressive supranuclear palsy: voxel-based investigations using f-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging.

Authors:  Ryuichi Takahashi; Kazunari Ishii; Tatsuya Kakigi; Kazumasa Yokoyama; Etsuro Mori; Takamichi Murakami
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2011-11-09

8.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Authors:  Gilbert Bensimon; Albert Ludolph; Yves Agid; Marie Vidailhet; Christine Payan; P Nigel Leigh
Journal:  Brain       Date:  2008-11-23       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.